Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | HMGCR | P04035 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | RORB | Q92753 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31291938 | 0.83 | NOTUM (0.44) | RORCRORBALDH1A1 | |
| SCHEMBL12127949 | 0.81 | ALDH1A1 (0.38) | RORCRORBGABRA1GRIN2DGRIN3B | |
| SCHEMBL387559 | 0.81 | ALDH1A1 (0.38) | RORCRORBGABRA1GRIN2DGRIN3B | |
| SCHEMBL27404530 | 0.79 | NPC1 (0.38) | GABRA1GABRB2ALDH1A1 | |
| SCHEMBL19294275 | 0.78 | ALDH1A1 (0.44) | NR1H4HMGCRGABRA1GABRB2ALDH1A1 | |
| SCHEMBL13172410 | 0.78 | FFAR4 (0.35) | NR1H4HMGCRGABRA1GABRB2GRIN2D | |
| SCHEMBL12024763 | 0.78 | CA1 (0.42) | GABRA1GABRB2ALDH1A1 | |
| SCHEMBL7803069 | 0.77 | KAT6A (0.36) | NR1H4HMGCRGABRA1GABRB2GRIN2D | |
| SCHEMBL13172494 | 0.77 | NR1H4 (0.34) | NR1H4HMGCRGABRA1GABRB2GRIN2D | |
| SCHEMBL17204044 | 0.76 | GABRA1 (0.39) | RORCRORBGABRA1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140275049-A1 | SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS | ELI LILLY AND COMPANY | 2014-09-18 | — | — | US | disclosed |
| WO-2013066640-A1 | SUBSTITUTED PYRAZOLE ANALOGUES AS RAR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275049-A1 | SUBSTITUTED PYRAZOLE ANALOGS As RAR ANTAGONISTS | RARB, RARA, RARG | NR1H4 94/4885HMGCR 3734/4885RORC 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.